Chikungunya Virus, PCR, Molecular Detection, Spinal Fluid
Use
The test provides qualitative detection of the chikungunya virus RNA in cerebrospinal fluid collected during the acute phase of infection, ideally less than 7 days from symptom onset. It is intended for patients with a clinical history and symptoms consistent with chikungunya virus infection. It is not recommended for screening healthy patients.
Special Instructions
Due to the short period in which chikungunya RNA may be detected in cerebrospinal fluid, it is recommended to also test serum for IgM and IgG antibodies to chikungunya virus. Additional forms may be necessary if not ordered electronically.
Limitations
Negative results do not preclude infection with chikungunya virus and should not be used as the sole basis for treatment or management decisions. False negatives may arise from degradation of the virus RNA due to incorrect storage or shipment conditions, or if collected after the typical detection period of seven days post-symptom onset. Specimens must not be heat inactivated, and all results must be interpreted in conjunction with clinical history and symptoms by a trained professional.
New York Approved
Methodology
PCR-based (RT-PCR)
Biomarkers
LOINC Codes
- 81153-9
- 81153-9
Result Turnaround Time
1-5 days
Related Documents
For more information, please review the documents below
Specimen
Cerebrospinal Fluid
Volume
0.5 mL
Minimum Volume
0.3 mL
Container
Sterile screw cap vial
Collection Instructions
Preferred collection container is vial number 2. Do not centrifuge or heat inactivate.
Causes for Rejection
Heat-inactivated specimen
Stability Requirements
| Temperature | Period |
|---|---|
| Refrigerated | 7 days |
| Frozen | 7 days |